Evidence map›Paper›PMID 35399329›Full record

ReviewOncology letters2022

Regulation of ROCK1/2 by long non-coding RNAs and circular RNAs in different cancer types.

Ammad Ahmad Farooqi, Rabbia Zahid, Humaira Naureen, Rukset Attar, Maria Gazouli, Rossana Berardi, Jolanta Szelachowska, Rafał Matkowski, Edyta Pawlak

Open access · diamondAbstract readReview
In one paragraph

Review in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  7. Article
  8. Long non-coding RNAs involved in retinoblastoma.Journal of cancer research and clinical oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Ammad Ahmad FarooqiDepartment of Molecular Oncology, Institute of Biomedical and Genetic Engineering, Islamabad 54000, Pakistan.
Rabbia ZahidInstitute of Chemistry, University of Punjab, Lahore 43000, Pakistan.
Humaira NaureenFaculty of Pharmaceutical Sciences, Riphah International University, Islamabad 54000, Pakistan.
Rukset AttarDepartment of Obstetrics and Gynecology, Yeditepe University 34280, Turkey.
Maria GazouliDepartment of Basic Medical Sciences, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens 54634, Greece.
Rossana BerardiOncology Clinic-Marche Polytechnic University, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, I-60126 Ancona, Italy.
Jolanta SzelachowskaDepartment of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland.
Rafał MatkowskiDepartment of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland.
Edyta PawlakDepartment of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 50-013 Wroclaw, Poland.
Wroclaw Medical University · PLInstitute of Biomedical and Genetic Engineering · PKLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLNational and Kapodistrian University of Athens · GROspedali Riuniti Umberto I · ITRiphah International University · PKUniversity of the Punjab · PKYeditepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent breakthroughs in high-throughput technologies have enabled the development of a better understanding of the functionalities of rho-associated protein kinases (ROCKs) under various physiological and pathological conditions. Since their discovery in the late 1990s, ROCKs have attracted the attention of interdisciplinary researchers due to their ability to pleiotropically modulate a myriad of cellular mechanisms. A rapidly growing number of published studies have started to shed light on the mechanisms underlying the regulation of ROCK1 and ROCK2 via long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in different types of cancer. Detailed analyses have suggested that lncRNAs may be characteristically divided into oncogenic and tumor suppressor lncRNAs. Several exciting recent discoveries have also indicated how different lncRNAs and circRNAs modulate ROCK1/2 and mediate multistep cancer onset and progression. The present review chronicles the major advances that have been made in our understanding of the regulatory role of ROCK1/2 in different types of cancer, and how wide-ranging lncRNAs and circRNAs potentiate ROCK-driven signaling by blocking the targeting activities of tumor suppressor microRNAs.

Indexed as

apoptosiscancermicroRNArho-associated protein kinasesignaling

Identifiers

PMID35399329
PMCPMC8987920
OpenAlexW4221030603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.